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Abstract: Different non-ionic cellulose ethers (methyl cellulose, MC; hydroxyethyl 
cellulose, HEC; hydroxypropyl cellulose, HPC; hydroxypropylmethyl cellulose, HPMC) 
and microcrystalline cellulose (MCC) were investigated as matrix formers for preparation 
of mini-tablets targeting vaginal drug delivery. Hexyl aminolevulinat hydrochloridum 
(HAL) was used as a model drug. The mini-tablets were characterized with respect to  
their mechanical strength, bioadhesion towards cow vaginal tissue in two independent tests 
(rotating cylinder test, detachment test using texture analyzer), and dissolution rate in two 
media mimicking the pH levels of fertile, healthy and post-menopausal women (vaginal 
fluid simulant pH 4.5, phosphate buffer pH 6.8). Mini-tablets with a matrix of either 
HPMC or HPC were found to possess adequate mechanical strength, superior bioadhesive 
behavior towards vaginal tissue, and pH independent controlled release of the model drug, 
suggesting that both systems would be suited for the treatment of women regardless of age, 
i.e., respective of their vaginal pH levels. Bioadhesive mini-tablets offer a potential for 
improved residence time in the vaginal cavity targeting contact with mucosal tissue and 
prolonged release of the drug. 
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1. Introduction 
The vagina is an important application site for drug delivery, especially for local therapy of 
different diseases, such as bacterial, fungal and protozoa infections, for HIV prevention, delivery of 
contraceptives, spermicides or labor-inducers and for the treatment of precancerous lesions [1,2].  
It may also serve an alternative route for systemic drug delivery [3]. 
Although the vaginal tissue is referred to as mucosal, the vagina does not have secretory glands. 
However, a mixture of fluids originating from a number of different sources comprises a moist film 
coating the vaginal surface. The pH of healthy pre-menopausal women of 3.5–4.5 is provided by lactic 
acid produced by the bacteria Lactobacillus, an essential part of the vaginal microflora [3,4].  
The composition, volume, pH and viscosity of the vaginal fluids are affected by age, cyclic hormone 
changes, and sexual activity; factors that may also influence the effect of vaginally applied drug 
delivery systems or dosage forms. Changes due to infections or pregnancy may also lead to different 
activity of drugs [3]. 
In order to maintain high patient compliance and adherence to therapy, the dosage forms or delivery 
systems should also be easy to administer and not cause discomfort or irritation. It should provide high 
efficiency based on an even distribution and long retention time of the drug in the vagina [3]. Different 
types of conventional dosage form, such as creams, gels, ointments and tablets, have been investigated 
for vaginal drug delivery, most of which has major drawback, and have been described as messy, 
uncomfortable, leaking in the underpants etc., resulting in low compliance. The low retention time  
is a well-known problem encountered in the formulation of drugs for vaginal application, and can  
also be attributed to the self-cleansing action of the vaginal tract [5,6]. Bioadhesive polymers are often 
included in the formulation to increase the retention time on the mucosal tissue [5,7]. The most widely 
investigated group of bioadhesive polymers are hydrophilic polymers containing numerous hydrogen 
bond forming groups, such as carbomers, chitosan, sodium aginate and cellulose derivatives [7]. Being 
water-soluble, the polymers become adhesive on exposure to moisture, and will readily cohere to 
surfaces. They are known to produce high viscosity at low concentrations, but most of the polymers 
are pH sensitive and may therefore behave differently depending on the vaginal pH. 
Lately, nanopharmaceuticals, e.g., liposomes, dendrimers, cyclodextrines and other nanoparticles, 
have gained attention also for vaginal delivery [6,8]. However, a major disadvantage of most 
nanopharmaceuticals is their liquid nature and their consequently low residence time within the vagina. 
Therefore, different types of vehicle have been proposed to prolong the retention time. Advanced 
delivery systems, such as liposomes-in-gels, have shown promising characteristics in in vitro and  
ex vivo experiments (e.g., [9,10]). Among advanced new systems from the research front that has 
entered into clinical trials can be mentioned: VivaGel® (Starpharma, Melbourne, Australia), which is a 
dendrimer-based antimicrobial platform targeting a range of sexual health products. VivaGel® is based 
on a Carbopol gel with acidic buffering capacity and mucoadhesive properties containing polylysine 
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dendrimers that binds to bacteria or viruses and prevents them from affecting the organism’s cells.  
The VivaGel® bacterial vaginosis (BV) has been confirmed to cure signs and symptoms of BV in 
Phase III clinical trials, and is currently undergoing studies to investigate the effectiveness in 
preventing reoccurrence of BV. The VivagGel® platform is also an interesting technology for 
prevention of transmission of genital herpes, HIV and other sexual transmitted infections including 
human papillomavirus (HPV), the causative agent of cervical cancer. Other examples of bioadhesive 
gel formulations are Carraguard®, a carrageenan based gel that has been shown to prevent transmission 
of high-risk HPV, but not HIV, in clinical trials by acting as an attachment inhibitor at the vaginal 
epithelium. An example of a bioadhesive gel which is on the market is Glynol II® Contraceptive Jelly, 
a spermicide containing gel (nonxynol-9) based on a combination of sodium carboxmethylcellulose 
and polyvinylpyrrolidone. Another promising approach is the foam technology platform from Foamix, 
targeting vaginal among other topical applications. The vaginal foam is bioadhesive emollient foam 
based on an o/w emulsion with a bioadhesive polymer. The company has different vaginal foams in the 
pipeline containing acyclovir, imiquimod and estradiol targeting herpes genitalis, genital warts and 
atrophic vaginitis, respectively. 
Solid formulations have the advantage of high dose accuracy and long term stability, as compared 
to semi-solid systems. However, the vaginal disintegration of conventional vaginal tablets is often 
slow, and the tablets are often rapidly cleared due to gravity combined with the self-cleansing action of 
the vagina. This may be circumvented by use of bioadhesive polymers in the formulation [11–13], but 
some studies also reported loss of bioadhesive tablets [11]. Multiparticulate systems (e.g., pellets or 
mini-tablets) can be used to overcome the problems associated with monolithic systems; the dose is 
divided into multiple smaller units that will spread out more in the vaginal cavity and contribute to 
improved coverage of the vaginal epithelium. Also, the loss of a few multiparticulates will have less 
impact of the outcome of the treatment. Bioadhesive multiparticulates are expected to swell and form 
micro-gels, releasing the drug in a controlled manner and maximizing the drug availability at the 
delivery site. Another multiparticulate approach for vaginal delivery is the microcrystalline starch 
pellets, which disintegrates in the vaginal cavity [14,15]. The pellets show fast disintegration also  
in vivo resulting in even distribution on the vaginal wall and prolonged retention of the formulation in 
the human vaginal cavity [16–19]. An alternative to the conventional solid dosage forms is intravaginal 
rings; e.g., a newly developed ring containing both an antiretroviral drug and a contraceptive has just 
entered into clinical trials [20]. 
The aim of the current study was to investigate bioadhesive mini-tablets for vaginal drug delivery. 
Mini-tablets are tablets with a diameter of 1–3 mm [21,22]. Hexyl aminolevulinat hydrochloridum 
(HAL) was chosen as a model drug because of its potential application in photodynamic therapy (PDT) 
of topical cancers, such as cervical cancer [2,23]. In PDT, a photoreactive substance (photosensitizer) 
is activated by illumination with light of a certain wavelength resulting in formation of reactive oxygen 
species, which will kill the cancer cells [24]. HAL is a derivative of the endogenous substance  
5-aminolevulinic acid (ALA), a precursor of the endogenous photosensitizer protoporphyrin IX (PpIX). 
Exogenous administration of 5-ALA, or its derivatives, induces accumulation of PpIX in cancerous 
lesions [25]. HAL is the hexyl-ester of 5-ALA. For clinical studies of cervical intraepithelial neoplasia 
(CIN), doses of 10 mL of 10 mM HAL-thermogel applied topically 5–9 h before photodynamic 
therapy have been reported [23,25]. HAL has a pKa of 8.31 for the amino-group and is freely  
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water-soluble (0.8 g in 1 g), but unstable in a moist environment [26,27]. Therefore, to eliminate the 
stability issues encountered with moist production steps, we propose direct compression as a suitable 
method for preparation of HAL mini-tablets. Non-ionic cellulose ethers were chosen as matrix formers 
since they are not influenced by changes in pH of the environment, and should therefore be expected to 
show the same performance in pre- and post-menopausal women. Bioadhesive properties were targeted 
to further prolong the retention of the mini-tablets on the vaginal mucosa. 
2. Experimental Section 
2.1. Materials 
Hexyl aminolevulinat hydrochloridum (HAL) was kindly provided by Photocure ASA, Oslo, 
Norway. Hypromellose (Hydroxypropylmethyl cellulose, HPMC) (Metolose 90SH-4000) was from 
Shin-Etsu Chemical Co, Tokyo, Japan, and hyprolose (hydroxypropyl cellulose, HPC) (Klucel® HF 
Pharm), hydroxyethyl cellulose (HEC) (Natrosol® 250LR) and methylcellulose (MC) (Culminal®  
MC-2000) were products of Hercules—Aqualon, Wilmington, Germany. Microcrystalline cellulose 
(MCC) (Avicel® PH101) was obtained from FMC biopolymers, Leeds, UK. Table 1 provides an 
overview of the polymers. 
Table 1. Overview of cellulose derivatives used in the current study. 
Polymer Substituent Group 
Molecular Weight 
(Dalton) * 
Microcrystalline cellulose (MCC) R = H <37,500 ** 
Methyl cellulose (MC) R = H or CH3 70,000 
Hydroxyethyl cellulose (HEC) R = H or CH2CH2OH 90,000 
Hydroxypropyl cellulose (HPC) R = H or CH2CH(OH)CH3 1,150,000 
Hydroxypropylmethyl cellulose (HPMC) R = H or CH3 or CH2CH(OH)CH3 1,200,000 
* Typical values according to product information; ** Estimated from degree of polymerization; not more 
than 350 according to European Pharmacopeia (Ph.Eur). 
2.2. Test Media 
Vaginal fluid simulant (VFS) was prepared by modification of the composition originally reported 
by Owen and Katz [3]. It contained 3.51 g/L NaCl, 1.40 g/L KOH, 0.222 g/L Ca(OH)2, 2 g/L lactic 
acid, 1 g/L acetic acid, 0.16 g/L glycerol, 0.4 g/L urea and 5 g/L glucose. The pH of the mixture was 
adjusted to 4.5 with either HCl or NaOH. 
Acetate buffer pH 4.5 was made by dissolving 77.1 g ammonium acetate in in distilled water.  
Seventy milliliter of glacial acetic acid was added and the mixture was diluted to 1000 mL with 
distilled water. 
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Phosphate buffer pH 6.8 was made from 51.0 mL 0.2 M KH2PO4 and 49.0 mL of 0.5 M Na2HPO4 
diluted to 1000 mL with distilled water. The pH was adjusted to 6.8 with either HCl or NaOH  
when necessary. 
2.3. Particle Density 
The true density of the polymers was determined using a helium gas pycnometer (AccuPyc 1330, 
Micromeritics Instrument Corporation, Norcross, GA, USA). Reported results were the mean of two 
independent experiments with 10 repetitive purge cycles and three runs for each experiment. 
2.4. Preparation of Tablets 
HAL was mixed separately with each of the polymers (MCC, HC, HEC, HPMC and HPC) in the 
ratio 10:90 (w/w) by hand, and compressed to mini-tablets on a costume-made compaction simulator 
(ServoPress 450, Schmidt Technology GmbH, St. Georgen, Germany, with the compaction module, 
IBR, Waldkirch, Germany) equipped with 2 mm concave 15-tip multiple tooling (Ritter Pharma–Technik 
GmbH, Stapelfeld, Germany). Prior to compression, the tips were lubricated using a magnesium 
stearate in acetone suspension. The mini-tablets were prepared by manual die-filling. The compaction 
speed was 10 mm/s. Compaction pressure was 150 ± 5 MPa. The filling volume was kept constant; 
hence, the mass of the biconvex mini-tablet varied depending on the density of the powder mixture. 
In addition, 6 mm flat-faced tablets were prepared following the same procedure, for use in the 
detachment test. 
For HPMC and HPC, additional formulations containing HAL to polymer in the ratio 1:99 and 
50:50 (w/w) were prepared both as 2 mm mini-tablets and 6 mm tablets. 
2.5. Mechanical Strength of the Mini-Tablets 
Thirty mini-tablets of each batch were evaluated with respect to height and crushing force using a 
texture analyzer (TA-XT2i Stable Micro Systems, Godalming, UK) with a 50 kg load cell at ambient 
temperature. For height measurements, the instrument was calibrated using calibration blocks DIN 861 
(W&Z Computer Vertrieb GmbH, Dresden, Germany) with the respective size of 1.000, 1.300, 1.400, 
1.500, 1.600, 1.700, 1.800, 1.900, 2.000, 2.100 and 3.000 mm. A calibration equation was derived, 
which was used for correction of the measured heights. The axial height of mini-tablets was 
determined using a speed of 0.10 mm/s and a trigger force of 5 g. The height registered at detection of 
the trigger force was taken as the mini-tablet height and corrected using the calibration equation. 
The diametrical force needed to crush the mini-tablet was determined at a speed of 0.3 mm/s 
applying a trigger force of 5 g. The tensile strength was calculated using the equation for flat-faced 
tablets according to Fell and Newton [28]. Even though min-tablets are biconvex, this approximation 
has been used in literature for estimation of tensile strength of mini-tablets [21,22]. 
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2.6. Ex Vivo Assessment of Bioadhesion 
2.6.1. Preparation of Tissue 
Cow vaginal mucosa was chosen as a biological matrix, since it is recognised as suitable for the 
simulation of human vaginal mucosa properties [10,12,29]. Vaginal mucosal tissue from heifer was 
obtained from the slaughterhouse (Mydland, Tromsø, Norway). The tissue was collected fresh, 
immediately after slaughtering, and transported in acetate buffer pH 4.5 on ice to the laboratory, where 
the vaginal mucosa was carefully removed from the underlying tissue and cleaned with acetate buffer 
pH 4.5. The tissue was cut into smaller pieces and packed in plastic (cling film) and aluminium foil 
before freezing at −20 °C. Prior to testing, the tissue was defrosted in acetate buffer pH 4.5 at  
37 ± 1 °C for 60 min using a magnetic stirrer and heated disc [29]. The tissue was cut into  
desirable-sized pieces and applied in the tests of bioadhesion. 
2.6.2. Rotating Cylinder Method 
The bioadhesion of mini-tablets to vaginal tissue was assessed in a modified version of the rotating 
cylinder method [30] as previously described [27]. Briefly, the vaginal tissue was attached to a 
cylinder, and 10 mini-tablets from the same batch were gently placed on the tissue without application 
of force. The cylinder with the tissue was placed in a chamber containing 400 mL acetate buffer  
pH 4.5 at 37 °C, and rotated at 150 rpm for 5 min. The number of mini-tablets remaining on the tissue 
after agitation was counted. The test was run in triplicate, and the results were given in percentage 
attached after agitation. 
2.6.3. Detachment Test 
The bioadhesiveness was studied further using in a texture analyzer (TA-XT2i Stable Micro 
Systems, Godalming, UK) with a 50 N load cell equipped with a mucoadhesion rig. The tablet was 
attached to a flat-faces probe using double-sided adhesive tape. Due to the small contact area of 
biconvex 2 mm mini-tablets, it was not possible to obtain appropriate results; therefore, 6 mm  
flat-faced tablets (prepared as described for mini-tablets) were employed in this test. The vaginal tissue 
(approximately 20 × 20 mm) was mounted in the holder and hydrated with 100 µL acetate buffer  
pH 4.5 (ambient temperature). After 1 min, the probe with the attached tablet was moved down to 
contact the tissue. The contact time between the tablet and the tissue was 30 s applying a force of 5.0 g. 
The probe was subsequently withdrawn at a constant speed of 0.1 mm/s. The maximum force 
registered in the detachment test was taken as the detachment force (Fmax) and the area under the curve 
(AUC) of the detachment force versus displacement was taken as the work of adhesion [31]. The test 
was run in eight parallels for each formulation. For reliable measurements, it is important that the 
registered detachment is in fact the detachment of the tablet from the tissue and not e.g., splitting of the 
tablet (due to capping/layering) or detachment of the tablet from the probe (adhesive tape), none of 
which were a problem in the current tests. 
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2.7. Dissolution Rate of Hexyl Aminolevulinat Hydrochloridum (HAL) from the Mini-Tablets 
Samples of approximately 400 mg (80 mini-tablets) were tested in 400 mL test medium using  
the paddle apparatus at 100 rpm and 37 ± 0.5 °C. As test media, vaginal fluid simulant pH 4.5 and 
phosphate buffer pH 6.8 were used. Samples of 2.0 mL were withdrawn after 5, 10, 15, 30, 45, 60 and 
120 min, respectively. The samples were filtered using 0.22 μm syringe filter (Merck Millipore, 
Darmstadt, Germany), and immediately quantified by HPLC–UV. The HPLC (Waters, Milford, CT, 
USA) method was based on reversed phase using a C8 column with 0.02 M phosphate buffer and 
methanol as the mobile phase (40/60), isocratic elution and UV-detection (Waters 2489 UV–vis 
detector) at 210 nm. The flow rate, injection volume and column temperature was set at 1.5 mL/min, 
50 µL and ambient temperature, respectively. HAL was quantified using external standard calibration 
(peak area). The method was validated with respect to precision as repeatability (RSD ≤ 2%), accuracy 
(60%–70%) and linearity (r = 0.992, range 70%–130% of target concentration). Results were 
calculated as mean (n = 3), and the variation expressed as highest and lowest deviation from the mean. 
2.8. Statistics 
Statistical significance of difference between formulations was determined using two-tailed 
Students t-test. p < 0.05 was considered statically significant. 
3. Results and Discussion 
The proper vaginal formulation should spread well out in the vaginal cavity to obtain good effect 
and have bioadhesive properties to ensure sufficiently long retention time at the delivery site and 
maximize drug activity. Previously, we have investigated multiparticulates of HAL prepared by 
extrusion/spheronization of Carbopol 934-containing blends [27]. Since HAL is sensitive to 
degradation in contact with moisture, the wet-massing step of the preparation process, and the 
remaining moisture content of the products resulted in poor storage stability of the formulations.  
By preparation of mini-tablets by direct compression, this issue is avoided. 
3.1. Preparation of Mini-Tablets 
Mini-tablets were prepared from all the different polymers in a drug to polymer ratio of 10:90 (w/w) 
(Table 2). The filling volume was kept constant for all formulations; since the polymers have different 
density, the mass of the mini-tablets varied between the formulations, with MCC producing the 
heaviest and HPC the least heavy units. 
The tensile strength of the mini-tablets showed varying mechanical strength, with those prepared 
with MCC being the strongest, followed by formulations with HPMC and HPC, respectively (Table 2). 
Mini-tablets prepared from MC and HEC possessed low mechanical strength. The strength of the HEC 
mini-tablets was border line with what is allowable with careful handling without falling apart. The 
mechanical strength reflects the formulation’s ability to form tablets by direct compression under the 
applied pressure (150 ± 5 MPa). The excipients producing the strongest tablets (MCC, HPC and 
HPMC) are frequently used as binders in direct compression and/or dry granulation [32], and therefore 
expected to produce strong tablets. MC and HEC may also be used as binder in tablet formulation, but 
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more in wet granulation, which could explain why the mechanical strength of the directly compressed 
mini-tablets was lower with these excipients. 
Table 2. Overview of particle density of the polymers and tensile strength of 2 mm biconvex 
mini-tablets consisting of 10% (w/w) hexyl aminolevulinat hydrochloridum (HAL) and 90% 
(w/w) of the respective polymers. 
Polymer Particle Density * [g/cm3] Tensile Strength ** [N/mm2]
Microcrystalline cellulose (MCC) 1.518 ± 0.008 3.09 ± 0.55 
Methyl cellulose (MC) 1.319 ± 0.002 0.46 ± 0.13 
Hydroxyethyl cellulose (HEC) 1.334 ± 0.001 0.13 ± 0.02 
Hydroxypropyl cellulose (HPC) 1.203 ± 0.001 1.30 ± 0.37 
Hydroxypropylmethyl cellulose (HPMC) 1.341 ± 0.001 1.42 ± 0.45 
* n = 6; ** n = 30. 
3.2. Bioadhesive Characteristics 
The two mechanically weak formulations, namely mini-tablets based on MC and HEC, were found 
to disintegrate immediately upon exposure to fluids. Thus, no results could be obtained with respect to 
their bioadhesive behaviour towards vaginal tissue. 
In the rotating cylinder test, none of the mini-tablets made of MCC were retained on the tissue after 
agitation (Figure 1). Mini-tablets containing HPC and HPMC showed high degree of retention on the 
vaginal tissue after agitation. More than 72% was retained for the HPC-based formulations and more 
than 93% was retained for the HPMC-based formulations. This is in the same order of magnitude as 
found for the most bioadhesive Carbopol 934-containing pellets in the previous study [27]. The 
rotating cylinder test showed a significant difference in bioadhesive behaviour between mini-tablets 
based on HPC and HPMC (p < 0.05). Furthermore, mini-tablets of HPMC also seemed to swell more, 
or more precisely increase more in size during swelling, as compared to those consisting of HPC. It has 
been shown in general terms that the swelling state of the polymer contributes to its bioadhesive 
characteristics [33]. The less hydrophobic character of HPMC compared to HPC may contribute to a 
higher swelling and hence the higher extent of bioadhesion observed for these mini-tablets towards the 
vaginal tissue. Also, the drug itself may contribute to the bioadhesive nature of the formulations; HAL 
is positively charged at pH 4.5 (pKa 8.31) and may therefore interact with the negatively charged 
tissue surface and with mucin. For HPMC and HPC formulations, it may seem like a correlation 
between retention of the mini-tablets on the tissue and their respective tensile strength; however, the 
highest tensile strength was found for the mini-tablet formulation with MCC, which did not show any 
retention to the tissue in the rotating cylinder method. 
To further quantify the bioadhesive character of the mini-tablets, the detachment test was employed. 
However, due to the biconvex shape of the mini-tablets and the small contact area both with the probe 
(double-sided tape) and the tissue, the mini-tablets detached more often from the probe than it 
detached from the vaginal tissue, and no reproducible measurements could be obtained. Therefore,  
to allow measurements, larger fat-faced tablets of 6 mm diameter were prepared with the same 
compositions as the mini-tablets. These allowed quantification of the max detachment force  
(Figure 2a) and the work of adhesion (Figure 2b). 
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Figure 1. Effect of the type of polymer on the bioadhesion of 2 mm biconvex mini-tablets 
to vaginal tissue represented as percentage of retained units on the tissue after applied 
stress in the rotating cylinder test; drug to polymer ratio 10:90 (w/w); (n = 30). Mini-tablets 
of methyl cellulose (MC) and hydroxyethyl cellulose (HEC) disintegrated and no result 
was obtained. 
 
Figure 2. Effect of the type of polymer on the bioadhesion of 6 mm flat-faced tablets to 
vaginal tissue in the detachment test; drug to polymer ratio 10:90 (w/w); (n = 8). (a) Max 
detachment force (Fmax); (b) Work of adhesion (AUC). Tablets of MC and HEC 
disintegrated and no result was obtained. 
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Figure 2. Cont.
 
(b) 
Even though the amount of fluid present during measurements was considerably lower in this test, 
the MC and HEC tablets started disintegrating upon contact with fluids, and no results were obtained 
for the two formulations. The highest detachment force and the highest work of adhesion were found 
for HPC and HPMC (Figure 2). The order of magnitude for the detachment force was in the lower 
region of what has been reported in a similar test for much larger tablets (13 mm diameter) composed 
of blends of HPMC and Carbopol [12]. Since the tablets in our study are significantly smaller (6 mm 
diameter), the contact area towards tissue is also smaller. In our study, no significant difference was 
observed in bioadhesion between the two polymers HPC and HPMC, but they showed significantly 
higher values in both detachment force and work of adhesion than MCC. 
MCC is generally not considered as a bioadhesive polymer, although it swells to a certain degree in 
water and has several hydrogen bond forming groups. The unexpectedly high detachment forces 
determined in the current study might be a result of interfering capillary forces, even though care was 
taken to avoid the influence of capillary forces on the measurements; prior to each test, both the tablet 
and tissue were well hydrated with acetate buffer pH 4.5. A well-hydrated tissue was chosen to better 
mimic the moisture-film coating the tissue of the vaginal cavity, as an excess of fluid is less 
biologically relevant. The production of vaginal fluid is reported to be around 6 g daily with 
approximately 0.5–0.75 g present in the vagina at any time [4]. The fact that the work of adhesion is 
relatively much lower for MCC-tablets as compared to the two other polymers supports the hypothesis 
of influencing capillary forces. It is less likely that capillary forces play a role in the case of the true 
bioadhesive polymers HPC and HPMC, as the surface layer swells quickly in contact with test medium 
and forms a gel-like surface. Also, the positive charge of HAL at this pH might contribute to the 
unexpectedly high detachment force observed for the MCC-formulations. 
Comparing the results obtained in the two bioadhesion tests, the main trends were similar. The 
rotating cylinder method differentiated between the bioadhesive capacity of HPC and HPMC, whereas 
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the detachment did not. This is probably attributed to the different test conditions rather than the 
properties of the polymers. Retrospectively, the detachment force registered for MCC suggests that 
capillary forces might have influenced this particular result. In the literature, a variety of tests are used 
to assess bio- and mucoadhesiveness [34]. The two tests applied in the current study are among the 
most commonly used. Interestingly, as pointed out in the review of Woertz et al. [34], even though the 
European Pharmacopeia monograph on oromucosal preparations contains a chapter on mucoadhesive 
preparations, it lacks an official standardized test for these preparations [35]. 
3.3. Dissolution Behavior 
The drug release from the mini-tablets was evaluated in two different media mimicking the pH of 
pre- and post-menopausal women. Vaginal fluid simulant (VFS) pH 4.5 was used to simulate the 
conditions of vaginal fluids in healthy, fertile women [4], whereas a more simple phosphate buffer  
pH 6.8 simulated the higher pH conditions post menopause [36]. Mini-tablets based on MCC, MC and 
HEC showed fast disintegration and the drug was released within 10–15 min in both media (Figure 3). 
The dissolution rate from HPC and HPMC mini-tablets were slower, with 80%–90% of the drug 
released after 60 min. The slowest release was seen for HPC mini-tablets. The formulations were 
found to behave similar in both media, suggesting that the formulations will not be influenced by the 
age-dependent pH level of the woman. This is beneficial in terms of developing a pharmaceutical 
product. It is of vital importance that the drug release characteristics are predictable and will show 
similar behavior in the population of potential users. 
Figure 3. Dissolution rate of HAL from 2 mm convex mini-tablets in two media; drug  
to polymer ratio 10:90 (w/w); (n = 3) (a) Vaginal fluid simulant pH 4.5; (b) Phosphate 
buffer pH 6.8. 
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Figure 3. Cont.
 
(b) 
The somewhat faster release found from mini-tablets of HPMC as compared to HPC can be 
attributed to the less hydrophobic character of HPMC, and higher degree of swelling discussed above. 
It should be noted that the dissolution test can merely rank the dissolution rate from the different 
formulations, and not simulate vaginal in vivo conditions. As mentioned above, the amount of vaginal 
fluid present in the vagina at any time is less than 1 g on average [4]. Also, agitation is expected to be 
much lower than that simulated in the dissolution apparatus. Therefore, the release must also be 
expected to be slower in vivo than indicated by this simple in vitro test. This is why the bioadhesive 
characteristics of the multiparticulates are of great importance to maximize the effect of the drug. 
3.4. Further Optimization 
Both mini-tablets based on HPC and HPMC seemed suitable for vaginal drug delivery, as they 
show bioadhesive nature towards vaginal tissue combined with a controlled release of the drug. 
Increasing the drug load in the mini-tablets leads to reduced amount of the matrix former. Additional 
mini-tablets of the ratio HAL to polymer 50:50 and 1:99 (w/w) were prepared to evaluate the effect of 
the drug load on the mechanical properties (Figure 4). As expected, the tensile strength of the tablets 
was reduced when the amount of polymer, working as dry binder, was reduced. However, at 50% 
(w/w) polymer content both HPC and HPMC were still able to produce appropriate mini-tablets with a 
tensile strength of approximately 0.75 N/mm2, which is adequate for handling related to packing, 
filling, transportation and use. No significant difference was found in the tensile strength by increasing 
the polymer content from 90% to 99% (w/w). It may be hypothesized that the available binding seats 
on particles of the 10:90 powder mixture are similar to that of the 1:99 powder mixture, resulting in 
tablets of similar mechanical strength. If the tensile strength increases with increasing polymer content 
due to increased fraction of the bond-forming material, it is likely that the tensile strength has reached 
a percolation threshold or a plateau around 90% (w/w) of polymer. 
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Figure 4. Effect of the polymer content on the tensile strength of 2 mm convex  
mini-tablets of HAL and polymer (n = 30). 
 
With respect to bioadhesion, no significant changes related to polymer content were observed in the 
detachment test. The dissolution rate of HAL was increased with reducing polymer content (Figure 5). 
The difference between 90% and 99% (w/w) polymer seemed larger for the more hydrophobic HPC  
as compared to the HPMC, where no significant difference was observed. However, reducing the 
polymer content to 50% resulted in an increased dissolution rate. Again, the dissolution test should 
merely be used to rank the formulations relative to each other, as the test conditions were not 
biorelevant with respect to amount of fluid and agitation. 
Figure 5. Effect of the polymer content (% w/w) on the dissolution rate of HAL from  
2 mm convex mini-tablets (n = 3). Formulations containing 90% hydroxypropylmethyl 
cellulose (HPMC) and hydroxypropyl cellulose (HPC) (dashed lines) are replotted from 
Figure 3 to ease interpretation. 
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In the current study, external lubrication with magnesium stearate in acetone was found to be 
sufficient, but for scale-up to industrial production, a lubricant needs to be included in the formulation. 
The less hydrophobic sodium stearyl fumarate seems as a suitable choice since it is less likely to 
influence the wetting and swelling of the polymers, as compared to the very hydrophobic magnesium 
stearate. Both formulations based on HPMC and HPC are assumed to possess suitable compression 
and compaction properties allowing scale up, however this remains to be demonstrated. Large scale 
production of mini-tablets could be regarded as challenging due to the small matrices potentially 
resulting in high variability, but products based on mini-tablets have been on the market for decades, 
(e.g., pancreatin products from Nordmark, Germany) proving that it is technologically feasible. 
An approximation to a therapeutic dose of HAL for PDT in CIN (cervical cancer) may be derived 
from clinical studies where they applied 10 mL of 10 mM HAL thermogel topically [23,25] to be 
around 25 mg HAL. For mini-tablets with a mass of 5.5 ± 5 mg per unit and a drug load of 10% (w/w), 
this corresponds to around 45 mini-tablet, or 250 mg mini-tablets. This is considered to be a feasible 
amount to administer in one application, yet entailing enough single units to maintain the advantages 
of multiparticulates. Therefore, mini-tablet formulations of HAL in 10:90 (w/w) with HPMC and HPC 
seem to be promising candidates for further in vivo studies. 
For administration, the new mini-tablet formulations might be filled into capsules, but clinical 
studies with volunteers have shown lack of correlation between in vitro and in vivo disintegration times 
for capsules, both with respect to hard gelatin and HPMC capsules, probably due to the low amount  
of vaginal fluid present [18,19]. Intravaginal disintegration times of more than 6 h were reported in 
several of the volunteers. Using an applicator that does not require packing of the multiparticulates into 
capsules, as suggested by Poelvoorde et al. [19], seems like a suitable way to eliminate the influence of 
capsule disintegration and deliver the mini-tablets intravaginally. It is anticipated that due to the small 
size, the mini-tablets will distribute evenly over the vaginal epithelium, and the bioadhesive nature will 
make them less sensitive to gravity and clearance, resulting in a longer residence time maximizing the 
effect of the drug. This still remains to be proven in in vivo studies. 
From a safety perspective, the irritation potential of new vaginal delivery systems is the most vital 
characteristics because irritation causes inflammation and can, in severe cases, lead to cell toxicity and 
tissue damage, which further may increase the transmission of diseases (e.g., [37]). Also, mild mucosal 
irritation, such as genital burning, itching and discharge, is highly undesired for these types of products. 
Non-ionic cellulose derivatives in contrast to ionic polymers are not expected to influence the local  
pH nor form ionic bonds with the mucosal surface. Hydroxyethylcellulose (HEC) is even used as the 
base of the “universal placebo” gel that is commonly used in efficacy and safety trials of new 
microbicides [38,39]. The “universal placebo” gel is an isotonic get that is proven not to cause mucosal 
irritation in the standard rabbit vaginal irritation test assay [38], in the slug mucosal irritation assay [40] 
as well as in humans [39]. Whereas tonicity has been shown to be important to prevent epithelial 
swelling or dehydration [40], dry formulations seems to be less irritating on the vaginal mucosa [15–18], 
unless they contain materials that are irritating as such. This is supported by the several vaginal tablet 
products on the market. It is therefore assumed that mini-tablets based on non-ionic cellulose ester will 
be non-irritating and safe, but this remains to be verified in clinical studies. 
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4. Conclusions 
Bioadhesive mini-tablets offer potential for improved residence time in the vaginal cavity targeting 
contact with mucosal tissue and prolonged release of the drug. Mini-tablets with a matrix  
of either HPMC or HPC were found to possess adequate mechanical strength, bioadhesive behavior 
towards cow vaginal tissue, and show pH independent controlled release of the drug, suggesting that 
both systems are equally suited for the treatment of both pre- and post-menopausal women. Mini-tablet 
formulations based on MC or HEC were mechanically weaker and disintegrated fast upon contact with 
fluids, and therefore released the full drug load within a few minutes. Bioadhesion towards vaginal 
tissue could not be successfully evaluated, either in the rotating cylinder test or in the detachment test. 
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